Modulation of HERG potassium channels by extracellular magnesium and quinidine.

Torsades de pointes is a polymorphic ventricular arrhythmia resulting from congenital or drug-induced (acquired) QT prolongation. Pharmacologic suppression of repolarizing potassium currents is one mechanism causing the acquired long QT (LQT) syndrome. Recent studies have linked mutations in a gene encoding a potassium channel subunit (HERG) to the LQT syndrome. Clinical experience indicates that intravenous magnesium sulfate is effective in reversing torsades de pointes, but the molecular basis of this effect is not understood. This study was designed to investigate the effects of extracellular magnesium (Mg2+) on HERG potassium currents. HERG potassium channels were expressed in Xenopus oocytes and in a human cell line and were examined by voltage-clamp methods. Extracellular Mg2+ (0.3-10 mM) caused a concentration-dependent shift in the membrane-potential dependence of HERG channel opening, causing a reduction in K+ current. This effect was much greater than that observed in another human delayed rectifier K+ channel, hKv1.5, suggesting a specific interaction with the HERG channel. Quinidine is an antiarrhythmic drug that also causes torsades de pointes under certain conditions. Quinidine (3 microM) inhibited HERG currents expressed in oocytes by 32.1 +/- 3.2% (n = 5), whereas 1 microM quinidine inhibited HERG currents in tsA201 cells by 75.8 +/- 2.4% (n = 12). Increasing extracellular Mg2+ did not relieve the inhibition by quinidine, but caused additional suppression. These results indicate that extracellular Mg2+ exerts a direct action on HERG potassium channels, resulting in suppression of outward repolarizing potassium current. It is concluded that modulation of this important K+ current is not the mechanism by which intravenous magnesium terminates drug-induced LQT and torsades de pointes. Potent suppression of HERG channel current by quinidine, compared with that of I(Ks) and I(Na), is a likely contributor to torsades de pointes arrhythmias.

[1]  B. Hille,et al.  Negative surface charge near sodium channels of nerve: divalent ions, monovalent ions, and pH. , 1975, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[2]  H. Strauss,et al.  Modulation of HERG affinity for E‐4031 by [K+]o and C‐type inactivation , 1997, FEBS letters.

[3]  M. Sanguinetti,et al.  A mechanistic link between an inherited and an acquird cardiac arrthytmia: HERG encodes the IKr potassium channel , 1995, Cell.

[4]  Voltage‐ and time‐dependent block of delayed rectifier K+ current in rabbit sino‐atrial node cells by external Ca2+ and Mg2+. , 1996, The Journal of physiology.

[5]  A. Moss,et al.  The Long QT Syndrome: Prospective Longitudinal Study of 328 Families , 1991, Circulation.

[6]  R. Tsien,et al.  Blockade of current through single calcium channels by Cd2+, Mg2+, and Ca2+. Voltage and concentration dependence of calcium entry into the pore , 1986, The Journal of general physiology.

[7]  G. Landes,et al.  Positional cloning of a novel potassium channel gene: KVLQT1 mutations cause cardiac arrhythmias , 1996, Nature Genetics.

[8]  A. Moss.  Molecular genetics and ventricular arrhythmias. , 1992, The New England journal of medicine.

[9]  P. Hess,et al.  Block of the L‐type Ca2+ channel pore by external and internal Mg2+ in rat phaeochromocytoma cells. , 1993, The Journal of physiology.

[10]  A. Brown,et al.  HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine. , 1996, Circulation.

[11]  D. Snyders,et al.  Effects of quinidine on the sodium current of guinea pig ventricular myocytes. Evidence for a drug-associated rested state with altered kinetics. , 1990, Circulation research.

[12]  Arthur J Moss,et al.  SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome , 1995, Cell.

[13]  M. Sanguinetti,et al.  Spectrum of HERG K+-channel dysfunction in an inherited cardiac arrhythmia. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[14]  M. Sanguinetti,et al.  Two components of cardiac delayed rectifier K+ current. Differential sensitivity to block by class III antiarrhythmic agents , 1990, The Journal of general physiology.

[15]  D. Melton,et al.  In vitro RNA synthesis with SP6 RNA polymerase. , 1987, Methods in enzymology.

[16]  R Lazzara,et al.  Multiple mechanisms in the long-QT syndrome. Current knowledge, gaps, and future directions. The SADS Foundation Task Force on LQTS. , 1996, Circulation.

[17]  D. Roden.  Risks and benefits of antiarrhythmic therapy. , 1994, The New England journal of medicine.

[18]  A. Moss,et al.  Clinical Aspects of the Idiopathic Long QT Syndrome a , 1992, Annals of the New York Academy of Sciences.

[19]  R. Lazzara.  Antiarrhythmic drugs and torsade de pointes. , 1993, European heart journal.

[20]  P. Schwartz,et al.  Evidence of Genetic Heterogeneity in Romano‐Ward Long QT syndrome: Analysis of 23 Families , 1994, Circulation.

[21]  D. Roden,et al.  Suppression of time-dependent outward current in guinea pig ventricular myocytes. Actions of quinidine and amiodarone. , 1991, Circulation research.

[22]  S. Priori,et al.  Long QT syndrome patients with mutations of the SCN5A and HERG genes have differential responses to Na+ channel blockade and to increases in heart rate. Implications for gene-specific therapy. , 1995, Circulation.

[23]  D. Snyders,et al.  A rapidly activating and slowly inactivating potassium channel cloned from human heart. Functional analysis after stable mammalian cell culture expression , 1993, The Journal of general physiology.

[24]  J. Seidman,et al.  Missense mutation in the pore region of HERG causes familial long QT syndrome. , 1996, Circulation.

[25]  A. Keren,et al.  Magnesium Therapy in Ventricular Arrhythmias , 1990, Pacing and clinical electrophysiology : PACE.

[26]  A. Keren,et al.  TORSADE DE POINTES: DEFINITIONS, CAUSATIVE FACTORS, AND THERAPY: EXPERIENCE WITH SIXTEEN PATIENTS , 1984, Annals of the New York Academy of Sciences.

[27]  Lippincott Williams Wilkins,et al.  The Sicilian gambit. A new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology. , 1991, Circulation.

[28]  A. Keren,et al.  Treatment of torsade de pointes with magnesium sulfate. , 1988, Circulation.

[29]  H. Strauss,et al.  A quantitative analysis of the activation and inactivation kinetics of HERG expressed in Xenopus oocytes , 1997, The Journal of physiology.

[30]  J. Garcia-Rubira,et al.  Magnesium sulphate for torsade de pointes in a patient with congenital long QT syndrome. , 1990, International journal of cardiology.

[31]  S. Roberds,et al.  Time-, voltage-, and state-dependent block by quinidine of a cloned human cardiac potassium channel. , 1992, Molecular pharmacology.

[32]  S. Priori,et al.  Cardiac sodium channel mutations in patients with long QT syndrome, an inherited cardiac arrhythmia. , 1995, Human molecular genetics.

[33]  D. Snyders,et al.  Functional expression of an inactivating potassium channel cloned from human heart. , 1992, Circulation research.

[34]  A. George,et al.  Molecular mechanism for an inherited cardiac arrhythmia , 1995, Nature.

[35]  D. Roden.  Clinical features of arrhythmia aggravation by antiarrhythmic drugs and their implications for basic mechanisms , 1990 .

[36]  S. Roberds,et al.  Heteromultimeric assembly of human potassium channels. Molecular basis of a transient outward current? , 1993, Circulation research.

[37]  Gary Yellen,et al.  The inward rectification mechanism of the HERG cardiac potassium channel , 1996, Nature.

[38]  M. Leppert,et al.  Locus heterogeneity of autosomal dominant long QT syndrome. , 1993, The Journal of clinical investigation.

[39]  J. Warmke,et al.  A family of potassium channel genes related to eag in Drosophila and mammals. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[40]  S Nattel,et al.  Sustained depolarization-induced outward current in human atrial myocytes. Evidence for a novel delayed rectifier K+ current similar to Kv1.5 cloned channel currents. , 1993, Circulation research.

[41]  D. Zipes,et al.  Torsades de pointes and proarrhythmia , 1993, The Lancet.

[42]  A. Keren,et al.  Magnesium therapy for torsades de pointes. , 1984, The American journal of cardiology.

[43]  S. Heinemann,et al.  Molecular determinants for activation and inactivation of HERG, a human inward rectifier potassium channel. , 1996, The Journal of physiology.

[44]  M. Sanguinetti,et al.  Class III antiarrhythmic drugs block HERG, a human cardiac delayed rectifier K+ channel. Open-channel block by methanesulfonanilides. , 1996, Circulation research.

[45]  C. Schuger,et al.  Treatment of torsade de pointes with intravenous magnesium. , 1989, The American journal of cardiology.